Policy & Regulation
Polaris to Utilise MD Anderson Cancer Center Immunotherapy Platform for Clinical Trials and Preclinical Research
15 May 2018 - - San Diego, California-based biotechnology company Polaris Group has signed a multiyear strategic collaboration agreement with MD Anderson Cancer Center to utilize its immunotherapy platform to design clinical studies and monitor biomarkers in immune functions associated with the therapies, the company said.
As one of the ten research platforms that support the Cancer Moon Shots Program, MD Anderson's immunotherapy platform conducts preclinical research to assess feasibility and efficacy of new treatments; it also monitors immune function changes as a result of clinical therapies through cellular and molecular analysis of patient samples in hope of discovering biomarkers for personalized medicine.
ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine.
Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow.
ADI-PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient's normal cells unharmed.
Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI-PEG 20.
Polaris Group specializes in the research and development of protein drugs to treat cancer and other debilitating diseases.
In addition to the ADI-PEG 20 program, Polaris Group is developing other therapeutic agents including a small molecule drug program that utilises a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.


Related Headlines